AT13148Multi-AGC kinase inhibitor,ATP-competitive CAS# 1056901-62-2 |
- GDC-0068 (RG7440)
Catalog No.:BCC1271
CAS No.:1001264-89-6
- AZD5363
Catalog No.:BCC1073
CAS No.:1143532-39-1
- H 89 2HCl
Catalog No.:BCC4997
CAS No.:130964-39-5
- Ro 31-8220 Mesylate
Catalog No.:BCC4999
CAS No.:138489-18-6
- AT7867 dihydrochloride
Catalog No.:BCC1378
CAS No.:1431697-86-7
- AT7867
Catalog No.:BCC2536
CAS No.:857531-00-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1056901-62-2 | SDF | Download SDF |
| PubChem ID | 24905401 | Appearance | Powder |
| Formula | C17H16ClN3O | M.Wt | 313.78 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (159.35 mM; Need ultrasonic) | ||
| Chemical Name | (1S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)phenyl]ethanol | ||
| SMILES | C1=CC(=CC=C1C2=CNN=C2)C(CN)(C3=CC=C(C=C3)Cl)O | ||
| Standard InChIKey | IIRWNGPLJQXWFJ-KRWDZBQOSA-N | ||
| Standard InChI | InChI=1S/C17H16ClN3O/c18-16-7-5-15(6-8-16)17(22,11-19)14-3-1-12(2-4-14)13-9-20-21-10-13/h1-10,22H,11,19H2,(H,20,21)/t17-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | AT13148 is an orally active and ATP-competitive, multi-AGC kinase inhibitor with IC50s of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively.In Vitro:AT13148 inhibits a panel of kinases at 10 μM, and the IC50 values for p70S6K, PKA, ROCKI, and ROCKII are all less than 10 nM and those for AKT1, 2, and 3 are 38, 402, and 50 nM, respectively. For the related AGC kinases RSK1 and SGK3, the IC50 values are 85 and 63 nM, respectively. In contrast, IC50 values for the non-AGC kinases CHK2 and Aurora B are both greater than 800 nM. AT13148 potently inhibits proliferation with GI50 values of 1.5 to 3.8 μM across a selected panel of cancer cell lines[1]. AT13148 treatment in gastric cancer cells dramatically suppresses activation of multiple AGC kinases, including Akt (at p-Thr-308), p70S6 kinase (p70S6K), glycogen synthase kinase 3β (GSK-3β) and p90 ribosomal S6 kinase (RSK)[2].In Vivo:Oral drug administration of 5 mg/kg of AT13148 results in complete bioavailability. Clear inhibition of phosphorylation of the AKT substrates GSK3β, tuberin, and the p70S6K target S6RP are also observed in PTEN-deficient MES-SA human uterine tumor xenografts after treatment with 40 and 50 mg/kg p.o. of AT13148[1]. Oral gavage of AT13148 at well-tolerated doses significantly inhibits HGC27 xenograft tumor growth in nude mice. AGC activity is also dramatically decreased in AT13148-administrated HGC27 tumors[2]. References: | |||||
AT13148 Dilution Calculator
AT13148 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.1869 mL | 15.9347 mL | 31.8695 mL | 63.7389 mL | 79.6737 mL |
| 5 mM | 0.6374 mL | 3.1869 mL | 6.3739 mL | 12.7478 mL | 15.9347 mL |
| 10 mM | 0.3187 mL | 1.5935 mL | 3.1869 mL | 6.3739 mL | 7.9674 mL |
| 50 mM | 0.0637 mL | 0.3187 mL | 0.6374 mL | 1.2748 mL | 1.5935 mL |
| 100 mM | 0.0319 mL | 0.1593 mL | 0.3187 mL | 0.6374 mL | 0.7967 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
AT13148 is a novel, oral and ATP-competitive inhibitor of multi-AGC Kinase with IC50 values of 38nM, 8nM, 3nM, 63nM and 4nM for AKT, p70S6 kinase, PKA, SGK and Rho kinase, respectively [1].
In vitro studies, AT13148 has been reported to inhibit activity of AGC kinases which including AKT, p70S6 kinase, PKA, SGK and Rho kinase with the IC50 values of 38nM, 8nM, 3nM, 63nM and 4nM, respectively. In addition, AT13148 has been revealed to inhibit proliferation with GI50 values of 1.54μM, 1.59μM, 1.82μM, 2.65μM and 3.77μM in MES-SA, BT474, HCT-116, A549 and SK-OV-3 cell lines, respectively.
In vivo studies, AT13148 has shown the antitumor activity in multiple human tumor xenograft models including PTEN-deficient MES-SA human uterine sarcoma, HER2-positive, PIK3CA-mutant BT474 human breast cancer xenografts [1].
References:
[1] Yap TA1, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3912-23.
- CYT387 sulfate salt
Catalog No.:BCC1506
CAS No.:1056636-06-6
- CYT387
Catalog No.:BCC2196
CAS No.:1056634-68-4
- Mizolastine dihydrochloride
Catalog No.:BCC4132
CAS No.:1056596-82-7
- ML 9 hydrochloride
Catalog No.:BCC6644
CAS No.:105637-50-1
- Hydroxyfasudil
Catalog No.:BCC1635
CAS No.:105628-72-6
- Fasudil (HA-1077) HCl
Catalog No.:BCC2542
CAS No.:105628-07-7
- Prostephanaberrine
Catalog No.:BCN4736
CAS No.:105608-27-3
- BMY 14802 hydrochloride
Catalog No.:BCC5759
CAS No.:105565-55-7
- Ginsenoside Rh3
Catalog No.:BCN1071
CAS No.:105558-26-7
- Fmoc-Glycinol
Catalog No.:BCC3094
CAS No.:105496-31-9
- Calceolarioside B
Catalog No.:BCN2787
CAS No.:105471-98-5
- Risedronate
Catalog No.:BCC4711
CAS No.:105462-24-6
- Androstanolone 17-benzoate
Catalog No.:BCC8825
CAS No.:1057-07-4
- AL 8697
Catalog No.:BCC8037
CAS No.:1057394-06-5
- Ganoderic acid C6
Catalog No.:BCN3257
CAS No.:105742-76-5
- Methyl ganoderate C6
Catalog No.:BCN3259
CAS No.:105742-81-2
- Fmoc-Ser(tBu)-OPfp
Catalog No.:BCC3545
CAS No.:105751-13-1
- Sitostenone
Catalog No.:BCN5868
CAS No.:1058-61-3
- E-3810
Catalog No.:BCC1541
CAS No.:1058137-23-7
- Nateglinide
Catalog No.:BCC5005
CAS No.:105816-04-4
- Tropisetron Hydrochloride
Catalog No.:BCC4027
CAS No.:105826-92-4
- TSTU
Catalog No.:BCC2828
CAS No.:105832-38-0
- Obtusilin
Catalog No.:BCN2697
CAS No.:105870-59-5
- (tert-Butoxycarbonyl)oxycefcapene pivoxil
Catalog No.:BCC8403
CAS No.:105889-80-3
Role of the anti-glioma drug AT13148 in the inhibition of Notch signaling pathway.[Pubmed:26187072]
Gene. 2015 Nov 15;573(1):153-9.
OBJECTIVE: To investigate the drug targets related to Notch signaling pathway for glioma treatment. METHODS: Gene expression profiles GSE44561, GSE48079 and GSE22772GSE48079GSE22772 of glioma cells samples with activated Notch signaling pathway and control samples were downloaded from Gene Expression Omnibus database to screen the differentially expressed genes (DEGs) using limma package. GO (Gene Oncology) function and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment analyses were conducted using DAVID tools to predict the underlying function of these DEGs. Sequentially, drug target genes recorded in DrugBank database were collected and matched with the selected DEGs to identify the potential drug targets for glioma. Further, these targets were verified by the screened DEGs in the anti-glioma drug (AT13148) treated samples of microarray data of GSE38008. RESULTS: A total of 75,645,497 DEGs were respectively identified in GSE44561, GSE48079 and GSE22772GSE48079GSE22772 datasets and these DEGs could well distinguish the glioma samples from controls. The DEGs were mainly enriched in classical functions and pathways, such as cell cycle, and DNA replication. A total of 122 DEGs were found to be potential drug targets for glioma, among which GLIPR1 was targeted by drug XL820, PDGFRB and KDR were targeted by SOT-107. Efficacy validation of the other 119 drug targets by GSE38008 data showed that ACSS1, ASL, GCLM, ROCK2, IMPA1, and TFPI may be targeted by the anti-glioma drug of AT13148. CONCLUSION: AT13148 may inhibit glioma progression by suppressing the Notch signaling genes, including GLIPR1, PDGFRB, ACSS1, and ASL.
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.[Pubmed:22781553]
Clin Cancer Res. 2012 Jul 15;18(14):3912-23.
PURPOSE: Deregulated phosphatidylinositol 3-kinase pathway signaling through AGC kinases including AKT, p70S6 kinase, PKA, SGK and Rho kinase is a key driver of multiple cancers. The simultaneous inhibition of multiple AGC kinases may increase antitumor activity and minimize clinical resistance compared with a single pathway component. EXPERIMENTAL DESIGN: We investigated the detailed pharmacology and antitumor activity of the novel clinical drug candidate AT13148, an oral ATP-competitive multi-AGC kinase inhibitor. Gene expression microarray studies were undertaken to characterize the molecular mechanisms of action of AT13148. RESULTS: AT13148 caused substantial blockade of AKT, p70S6K, PKA, ROCK, and SGK substrate phosphorylation and induced apoptosis in a concentration and time-dependent manner in cancer cells with clinically relevant genetic defects in vitro and in vivo. Antitumor efficacy in HER2-positive, PIK3CA-mutant BT474 breast, PTEN-deficient PC3 human prostate cancer, and PTEN-deficient MES-SA uterine tumor xenografts was shown. We show for the first time that induction of AKT phosphorylation at serine 473 by AT13148, as reported for other ATP-competitive inhibitors of AKT, is not a therapeutically relevant reactivation step. Gene expression studies showed that AT13148 has a predominant effect on apoptosis genes, whereas the selective AKT inhibitor CCT128930 modulates cell-cycle genes. Induction of upstream regulators including IRS2 and PIK3IP1 as a result of compensatory feedback loops was observed. CONCLUSIONS: The clinical candidate AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors. AT13148 will now be assessed in a first-in-human phase I trial.
AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo.[Pubmed:26828267]
Biochem Biophys Res Commun. 2016 Sep 9;478(1):330-336.
The AGC kinase family is important cell proliferation and survival. Dysregulation of this family contributes to gastric cancer progression. Here, we evaluated the potential activity of AT13148, a first-in-class multi-AGC kinase inhibitor, against gastric cancer cells. Our results showed that AT13148 exerted potent cytotoxic and anti-proliferative activities against a panel human gastric cancer cell lines (HGC-27, AGS, SNU-601, N87 and MKN-28), possibly via inducing cancer cell apoptotic death. Apoptosis inhibition by the Caspase blockers dramatically attenuated AT13148-caused cytotoxicity against gastric cancer cells. Intriguingly, same AT13148 treatment was not cytotoxic/pro-apoptotic to the non-cancerous human gastric epithelial GEC-1 cells. At the signaling level, AT13148 treatment in gastric cancer cells dramatically suppressed activation of multiple AGC kinases, including Akt (at p-Thr-308), p70S6 kinase (p70S6K), glycogen synthase kinase 3beta (GSK-3beta) and p90 ribosomal S6 kinase (RSK). Our in vivo studies demonstrated that daily oral gavage of AT13148 at well-tolerated doses significantly inhibited HGC27 xenograft tumor growth in nude mice. AGC activity was also dramatically decreased in AT13148-administrated HGC27 tumors. Therefore, targeting AGC kinases by AT13148 demonstrates superior anti-gastric cancer activity both in vitro and in vivo. The preclinical results of this study support the progression of this molecule into future evaluation as a valuable anti-gastric cancer candidate.
